Immunotherapy of triple negative breast cancer
dc.contributor.author | Dvořák Josef | cs |
dc.contributor.author | Richter Igor | cs |
dc.contributor.author | Prokš Jan | cs |
dc.contributor.author | Rozsypalová Aneta | cs |
dc.contributor.author | Grimová Jana | cs |
dc.date.accessioned | 2020-06-08T09:45:58Z | |
dc.date.available | 02-12-2020 | en |
dc.date.available | 2020-06-08T09:45:58Z | |
dc.date.issued | 2019 | cs |
dc.date.updated | 28-20-2020 | en |
dc.format.extent | 3 | cs |
dc.identifier.issn | 2464-7195 | cs |
dc.identifier.uri | https://dspace.tul.cz/handle/15240/156238 | |
dc.language.iso | cze | cs |
dc.publisher | Current Media s.r.o. | cs |
dc.relation.ispartof | Onkologická review 2019 | en |
dc.relation.ispartofseries | 0 | cs |
dc.subject | triple negative breast cancer | cs |
dc.subject | immunotherapy | cs |
dc.subject | check point inhibitors | cs |
dc.subject | atezolizumab | cs |
dc.title | Immunotherapy of triple negative breast cancer | en |
dc.title | Imunoterapie triple negativního karcinomu prsu | cs |
local.citation.epage | 79-81 | cs |
local.citation.spage | 79-81 | cs |
local.identifier.publikace | 6946 | |
local.relation.issue | 4 | cs |